Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 497Rectal Neoplasms 268Colonic Neoplasms 219Pancreatic Neoplasms 188Stomach Neoplasms 183Esophageal Neoplasms 135Breast Neoplasms 119Neoplasm Metastasis 117Squamous Cell Carcinoma of Head and Neck 95Head and Neck Neoplasms 92Neoplasms 90Adenocarcinoma Of Esophagus 67Esophageal Squamous Cell Carcinoma 62Carcinoma, Hepatocellular 56Adenocarcinoma 40Nasopharyngeal Carcinoma 35Cholangiocarcinoma 32Biliary Tract Neoplasms 27Anus Neoplasms 26Gastrointestinal Neoplasms 25Carcinoma, Squamous Cell 25Carcinoma, Non-Small-Cell Lung 25Keratosis, Actinic 23Gallbladder Neoplasms 22Liver Neoplasms 21Urinary Bladder Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 20Bile Duct Neoplasms 19Ovarian Neoplasms 16Carcinoma 16

Interventions

Cetuximab 2Bevacizumab 2trifluridine tipiracil drug combination 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
mCRC × Fluorouracil × Clear all
NCT03567629 2018-06-26

Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer

Peking University

Phase 2 Unknown
130 enrolled

mCRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡